← Back to screener

Lexeo Therapeutics, Inc. LXEO

Rank #2114 · Nasdaq · $0.2B market cap
Audited by KPMG LLP, no going-concern flag in the latest filing.
Score
33.3
P/E
-2.5
P/B
2.17
ROE
-86.6%
Op. Margin
–%
Debt Ratio
27%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★★☆☆☆
Weak

P/E -2.5x, P/B 2.17x. Ranks in the top 66% of the universe.

Profitability ★☆☆☆☆
Poor

ROE -86.6%. Ranks in the top 93% of the universe.

Safety ★★★★☆
Excellent

Debt ratio 27%. Ranks in the top 15% of the universe. Under 100% is generally considered a safe level.

Growth –
No data

Not enough historical filings to compute year-over-year growth yet.

Safety is the relative strength · Profitability is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2023$0.0B$-0.1B$-0.1B$-0.1B-9252.1-45
2024–$-0.1B$-0.1B$-0.1B–-23
2025–$-0.1B$-0.1B$0.1B–27

← See the full screener